Deals Of The Week: Pfizer/Halozyme, Celgene/Sutro Biopharma, Amgen/ImmunoGen
Executive Summary
The week before Christmas proved to be an extraordinarily busy one for biopharmaceutical business development, highlighted by a Pfizer deal to enhance delivery of its biologics, an ALS research consortium led by Biogen Idec and the merger of two European companies, creating vaccine- and antibody-focused Valneva.
You may also be interested in...
Merck Partners On Alzheimer’s Diagnostic With GE Healthcare
Merck will use GE Healthcare’s investigational imaging agent flutemetamol to select patients to enroll in its clinical trial studying the oral BACE inhibitor MK-8931, with a particular emphasis on a future study in Alzheimer’s patients with mild cognitive impairment.
Celgene Dips Into The Antibody Well Once More, Partners With Sutro
Celgene Corp. has deepened its investment in antibody R&D, striking a collaboration with Sutro Biopharma to design and develop next-gen antibodies and to manufacture a proprietary Celgene candidate. Sutro gets cash, biobucks, and hi-profile validation of its multi-faceted non-cell antibody platform.
MorphoSys Finds Right Time To Focus On Pipeline With AbD Serotec Sale To Bio-Rad Labs
MorphoSys sells some of its assets in an effort to concentrate on its proprietary therapeutic endeavors – including a mid-stage rheumatoid arthritis drug.